| Outcome Measures: |
Primary: Change in beta-cell function as measured by change in C-peptide level during thd MMTT (Mixed meal tolerance test) at Day 112 compared to baseline (Day 0 pre-dose), Day 0 pre-dose and Day 112 | Secondary: Safety assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and treatment-emergent adverse events., Day 0 (baseline) through Day 364|Change in insulin requirements, Day -3 through Day 0 pre-dose and Day 109 through Day 112)|Change in HbA1c levels, Day 0 pre-dose and Day 112|Change in fasting glucose, Day 0 pre-dose and Day 112|Change in fasting glucagon and cortisol, Day 0 pre-dose and Day 112|Change in systemic inflammation markers, Day 0 pre-dose and Day 112|Change in meal-stimulated GLP-1 and GIP, Day 0 pre-dose and Day 112|Change in lipids profile, Day 0 pre-dose and Day 112|Measurement of serum concentrations of XOMA 052, Day 0 pre-dose, Day 28, Day 56, Day 84, Day 112, Day 182, and Day 364
|
